Poll Finds Overwhelming Public Support for Regulated Peptide Access

Conducted by Mason-Dixon Polling & Strategy for the advocacy group Peppies.com, the survey of 1,000 adults arrives just before the FDA’s Pharmacy Compounding Advisory Committee convenes on July 23–24 to discuss the regulatory status of seven specific peptides. While 45% of respondents remain undecided, the data suggests that among those with an established opinion, support for a legal prescription route outweighs opposition by a 19-to-1 margin.

Ken Underwood, founder of Peppies, argues that the current "peptide roulette" forces consumers toward unregulated overseas markets. Data supports the existence of this grey market: U.S. imports of peptide compounds from China reached approximately $328 million in the first three quarters of 2025. Safety concerns remain high, as testing by nonprofits ECRI and the Institute for Safe Medication Practices has uncovered products with purity levels as low as 5%, often contaminated with arsenic and lead exceeding toxicity thresholds for injectable drugs. Despite these risks, the survey indicates that 5% of adults report household usage of compounded peptides within the last three years, driven by a lack of domestic alternatives.